Desentum
Manufacturing · Finland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Perustie A 13 7, Helsinki, Uusimaa, 0033...Phone Number
+358 500512934Website
www.desentum.fiRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Desentum
Desentum is a biopharmaceutical company based in Espoo, Finland. It is specialized in developing a novel type of allergen immunotherapy based on switching the immune system's response to allergens from hypersensitivity to tolerance by utilizing modified hypoallergens. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Centre of Finland Ltd. In 2013 VTT received an EARTO (European Association of Research and Technology Organisations) Innovation Prize for the work behind the immunotherapeutic products. In 2018, Desentum was awarded a 1,9 M€ grant from the highly competitive Horizon 2020 SME instrument for the first-in-human clinical trial and business development.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Desentum your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Desentum, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Desentum launches new products
Congratulate Masked Content for being promoted to Masked Content at Desentum
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Desentum recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Desentum has recently received funding, and reach out quickly before it becomes old news!
Check out if Desentum is spiking on competitors!
Funding: Get notified immidiatlly once Desentum has new funding data
Click to see if Desentum had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Desentum is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Desentum is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Desentum.
Desentum financials insights
Gather financial insights about Desentum, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$2M
2019
Other Financing Round
$4.5M
2022
Unspecified
$9M
Desentum Tech Stack
A closer look at the technologies used by Desentum
See more technologies
Desentum News & Media
Desentum Raises M€8 in Funding
Desentum, an Espoo, Finland-based biopharmaceutical company advancing an allergy vaccine candidate, raised 8 M€ in funding. The round was arranged by Springvest Oyj. The company intends to use the funds for funding further clinical development, R&D of new hypoallergens and business development. Led by Pekka Mattila, CEO, Desentum develops novel immunotherapeutic hypoallergens, so called allergy […] The post Desentum Raises M€8 in Funding appeared first on FinSMEs.Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate
Finnish biopharmaceutical company Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj. Desentum intends to use the proceeds for funding further clinical development, R&D of new hypoallergens and business development. Desentum develops novel immunotherapeutic hypoallergens, so called allergy vaccines. The hDesentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, today announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a favourable immunological response. “We are very happy to have completed the clinical study despite the challenges posed by the Covi
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Desentum
Sign Up For FreeTo access detailed company insights
Desentum is a biopharmaceutical company based in Espoo, Finland. It is specialized in developing a novel type of allergen immunotherapy based on switching the immune system's response to allergens from hypersensitivity to tolerance by utilizing modified hypoallergens. Desentum, founded in 2011, is a spin-off company from VTT Technical Research Cent... Read More
